Beam Therapeutics Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Earlier in May 2026, Beam Therapeutics presented updated Phase 1/2 BEAM-302 data in alpha-1 antitrypsin deficiency, including detailed safety, durability and human neutrophil elastase findings, and confirmed plans to seek an accelerated approval path with an expanded pivotal cohort of about 50 additional patients starting in the second half of 2026. The data suggest BEAM-302’s one-time base-editing approach may address both liver and lung manifestations of AATD while preserving natural,...
Earlier in May 2026, Beam Therapeutics presented updated Phase 1/2 BEAM-302 data in alpha-1 antitrypsin deficiency, including detailed safety, durability and human neutrophil elastase findings, and confirmed plans to seek an accelerated approval path with an expanded pivotal cohort of about 50 additional patients starting in the second half of 2026. The data suggest BEAM-302’s one-time base-editing approach may address both liver and lung manifestations of AATD while preserving natural,...
Are there significant gains ahead for one (or both) of these innovative biotechs?
Are there significant gains ahead for one (or both) of these innovative biotechs?
Beam Therapeutics Inc. (BEAM) RBC Capital Markets Global Healthcare Conference 2026 May 20, 2026 10:30 AM EDTCompany ParticipantsJohn Evans - CEO &...
2026-05-20. The following slide deck was published by Beam Therapeutics Inc.
Beam Therapeutics (NASDAQ:BEAM) Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics license application for its sickle cell disease candidate possible as early as the end of this year. Sp
Beam Therapeutics (NASDAQ:BEAM) Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics license application for its sickle cell disease candidate possible as early as the end of this year. Sp
Beam Therapeutics Inc (NASDAQ:BEAM) is one of the best gene therapy stocks to buy in 2026. The stock is up roughly 27% in the past six months and soared more than 60% in the past year. The Street expects BEAM stock to pop almost 70% in the next 12 months as therapy programs continue to […]
Beam Therapeutics Inc (NASDAQ:BEAM) is one of the best gene therapy stocks to buy in 2026. The stock is up roughly 27% in the past six months and soared more than 60% in the past year. The Street expects BEAM stock to pop almost 70% in the next 12 months as therapy programs continue to […]
NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.
NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.
Beam Therapeutics (NasdaqGS:BEAM) reported positive Phase 1/2 data for its BEAM-302 program at a major international conference. The gene editing therapy showed durable restoration of alpha-1 antitrypsin function, targeting both lung and liver manifestations of the disease. Beam plans to expand the BEAM-302 trial and work with the FDA on a potential accelerated approval pathway. For investors watching genetic medicine, this update puts Beam Therapeutics back in focus. The stock last closed...
Beam Therapeutics (NasdaqGS:BEAM) reported positive Phase 1/2 data for its BEAM-302 program at a major international conference. The gene editing therapy showed durable restoration of alpha-1 antitrypsin function, targeting both lung and liver manifestations of the disease. Beam plans to expand the BEAM-302 trial and work with the FDA on a potential accelerated approval pathway. For investors watching genetic medicine, this update puts Beam Therapeutics back in focus. The stock last closed...
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Post-BEAM-302 TreatmentCAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitry
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.
BEAM-302 is being evaluated in a Phase 1/2, open-label, dose exploration and dose expansion clinical trial to investigate its safety, tolerability, pharmacodynamics, pharmacokinetics and efficacy. Topline data from 29
AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation (A1F), today announced Beam Therapeutics as an inaugural industry sponsor. The support further strengthens efforts to accelerate routine targeted detection of Alpha-1 Antitrypsin Deficiency (Alpha-1) in people impacted by liver and/or lung disease, consistent with clinical practice guidelines.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 12.45M | $296.74M | 0.02% | Added+4.6% | 2026-03-31 |
| ARKK | disruptive | 12.13M | $289.14M | 2.25% | Trimmed-2.7% | 2026-03-31 |
| StateStreet | passive | 5.70M | $135.81M | 0.00% | Added+9.0% | 2026-03-31 |
| TwoSigma | quant | 1.21M | $28.85M | 0.02% | Added+8.1% | 2026-03-31 |
| RenTech | quant | 513.6K | $12.24M | 0.02% | Added+228.2% | 2026-03-31 |
| Wellington | fundamental | 38.8K | $925.18K | 0.00% | Added+5.2% | 2026-03-31 |
| TRowePrice | fundamental | 2.71M | $64.66K | 0.01% | Trimmed-0.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-04upcoming | -1.13 | — | — |
| 2026-05-07 | -1.01 | -0.91 | +10.06% |
| 2026-02-24 | -1.12 | 2.33 | +308.96% |
| 2025-11-04 | -1.01 | -1.10 | -8.95% |
| 2025-08-05 | -1.09 | -1.00 | +8.36% |
| 2025-05-06 | -1.17 | -1.24 | -5.86% |
| 2025-02-25 | -1.22 | -1.09 | +10.34% |
| 2024-11-05 | -1.18 | -1.17 | +0.93% |
| 2024-08-06 | -1.12 | -1.11 | +0.73% |
| 2024-05-07 | -1.39 | -1.21 | +12.90% |
| 2024-02-27 | -0.71 | 1.73 | +343.61% |
| 2023-11-08 | -1.27 | -1.22 | +3.73% |
| 2023-08-08 | -1.38 | -1.08 | +21.59% |
| 2023-05-10 | -1.30 | -1.33 | -2.01% |
| 2023-02-28 | -1.34 | -0.54 | +59.56% |
| 2022-11-07 | -1.09 | -1.56 | -43.24% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BEAM | +7.26% | +20.98% | +18.80% | +108.02% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +4.29% | +25.62% | +22.24% | +95.33% |